American Society of Hematology

SHERPA: Blue

People

  1. Hultcrantz
    Hultcrantz
  2. Mailankody
    Mailankody
  3. Korde
    Korde
  4. Lesokhin
    Lesokhin
  5. Hassoun
    Hassoun
  6. Landau
    Landau
  7. Giralt
    Giralt
  8. Shah
    Shah
  9. Shah
    Shah
  10. Chung
    Chung

Groups

  1. Center for Hematologic Malignancies (89)
  2. Department of Medicine (89)
  3. Hematologic Malignancies, Division of (89)
  4. Myeloma (89)
  5. Sloan Kettering Institute Postdocs (89)
  6. Hematologic Malignancies Research (61)
  7. Survivorship Research (52)
  8. Bone Marrow Transplant (45)
  9. CTCR Scholars (44)
  10. Epidemiology and Biostatistics (43)
Search Within
  1. "Malin Hultcrantz"
Formats
  1. Meeting Abstract (86)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (89)
  2. Department of Medicine (89)
  3. Hematologic Malignancies, Division of (89)
  4. Myeloma (89)
  5. Sloan Kettering Institute Postdocs (89)
  6. Hematologic Malignancies Research (61)

More Groups

People
  1. Malin Hultcrantz (89)
  2. Sham Mailankody (50)
  3. Neha Korde (49)
  4. Alexander Lesokhin (48)
  5. Hani Hassoun (46)
  6. Heather Landau (42)

More People

Years
  1. 2024 (1)
  2. 2023 (19)
  3. 2022 (22)
  4. 2021 (11)
  5. 2020 (11)
  6. 2019 (6)

More Years

Publications
  1. Blood (86)
  2. Blood Advances (3)

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) sub-protocol Y3
    Meeting Abstract

    Richter, J.; Zonder, J. A.; Nathwani, N.; Bianchi, G.; Hofmeister, C. C.; Vij, R.; Pianko, M.; Kaur, G.; Hultcrantz, M.; Wozniak, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Risk factors of smoldering multiple myeloma: Results from the screened iStopMM study
    Meeting Abstract

    Thorsteinsdottir, S.; Sverrisdottir, I.; Rögnvaldsson, S.; Ekberg, S.; Hultcrantz, M.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • SARS-CoV-2 infection does not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study
    Meeting Abstract

    Palmason, R.; Ekberg, S.; Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Crowther, M.; Reed, E. R.; Oskarsson, J.; Sigurdardottir, G. A.; Aspelund, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The complex structural variant chromothripsis can be defined on targeted sequencing panels, allowing direct clinical translation in order to improve multiple myeloma prognostication
    Meeting Abstract

    Maclachlan, K. H.; Ziccheddu, B.; Tan, C.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Diamond, B.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save